Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14195)	7/23/2000 12:27:21 AM
From: Bluegreen	Respond to of 17367

Cacaito, it that really you????<g> Once again, when you start cooking there is NO SUBSTITUTE! Thanks for the treatise on dysfunctional fibrinogen activation. One area that needs to be explored is whether this activation is really quantitative or not and why some are more resistant to the kick off than others. You know a big interest for me is LBP and CD14 relationship. You gotta keep wondering why BPI keeps popping up and WHY is BPI in eosinophils????? I hope you will listen to the upcoming Xoma conference call and ask questions.

To: Cacaito who wrote (14195)	7/23/2000 8:17:05 AM
From: StockDoc	Read Replies (2) \| Respond to of 17367

Great research, I enjoyed reading it. I'd be somewhat more careful before jumping into conclusions. Just note that we don't know yet how much bleeding rhAPC (all the other fancy thrombosis drugs in the pipelines) causes at what doses. APC blocks the common (tissue factor + intrinsic) pathways and enhances fibrinolysis. In real life (Phase III and IV) I anticipate a few major (fatal) bleeding complications with the TFPI drug (Tifacogin), as TFPI "has been designed" by evolution to stop blood loss after injury. As of the drug combination issue you either did not read my note carefully or we don't agree. Either way, there's nobody in the world who could prevent me (us) from using, after purchase (!) two independently marketed drugs in combination at any dose in any of my (our) patients. The law is crystal clear (another great research project for you) and I (we) could not care less who patented what.